Cabozantinib (Cabometyx) for the follow-up treatment of advanced renal cell cancer
In 2018 the Institute for Quality and Efficiency in Health Care (IQWiG, Germany) looked into whether cabozantinib (trade name: Cabometyx) offers advantages or disadvantages for adults who have had treatment before when compared with the standard treatments. The drug manufacturer submitted one relevant study to IQWiG. This study only involved patients who had already had treatment aimed at the vascular endothelial growth factor (VEGF).
The study involved 658 people. Half of the patients received cabozantinib, the other half had treatment with everolimus. The study showed the following results for them:
What are the advantages of cabozantinib?
- Life expectancy: The study suggests that treatment with cabozantinib can prolong life more than everolimus. Half of the patients who received cabozantinib died after about 21 months. This happened after only about 17 months in the group that had treatment with everolimus.
- Anemia and pneumonia: The study suggests that cabozantinib has an advantage for these side effects.
What are the disadvantages of cabozantinib?
- Serious side effects: The study suggests that cabozantinib has a disadvantage here: In half the participants who had treatment with cabozantinib serious side effects already occurred after about 2 months, while it took about 4 months with everolimus. The study suggests that Cabozantinib has a disadvantage in terms of diarrhea, too: While half the participants who received cabozantinib experienced diarrhea already within about 2 months, the same was the case with everolimus only after almost 23 months.
- High blood pressure and hand-foot syndrome: The study suggests that cabozantinib has a disadvantage in terms of these side effects, too.
There was no discernible difference between the treatments in terms of symptoms of the disease, general health, and stopping treatment.
What remains unanswered?
The manufacturer didn't provide any suitable data about health-related quality of life.
Institute for Quality and Efficiency in Health Care (IQWiG, Germany). Cabozantinib (renal cell carcinoma) – Addendum to Commission A17-56. Commission A18-13. March 09, 2018. (IQWiG reports; Volume 603).
Institute for Quality and Efficiency in Health Care (IQWiG, Germany). Cabozantinib (renal cell carcinoma) – Addendum to Commission A17-56. Commission A18-18. March 15, 2018. (IQWiG reports; Volume 606).
Institute for Quality and Efficiency in Health Care (IQWiG, Germany). Cabozantinib (renal cell carcinoma) – Benefit assessment according to §35a Social Code Book V. Dossier assessment; Commission A17-56. January 11, 2018. (IQWiG reports; Volume 583).
IQWiG health information is written with the aim of helping
people understand the advantages and disadvantages of the main treatment options and health
Because IQWiG is a German institute, some of the information provided here is specific to the German health care system. The suitability of any of the described options in an individual case can be determined by talking to a doctor. informedhealth.org can provide support for talks with doctors and other medical professionals, but cannot replace them. We do not offer individual consultations.
Our information is based on the results of good-quality studies. It is written by a team of health care professionals, scientists and editors, and reviewed by external experts. You can find a detailed description of how our health information is produced and updated in our methods.